Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes

CONTEXT: Cardiovascular benefits of empagliflozin in patients with type 2 diabetes mellitus (T2DM) have been reported; however, the underlying mechanism remains unknown. OBJECTIVE: We hypothesized that the cardiovascular benefits of empagliflozin are associated with altered gut microbiota and plasma...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Xinru, Zhang, Chenhong, Wang, Pengxu, Wei, Wei, Shi, Xiaoyang, Wang, Pingping, Yang, Junpeng, Wang, Limin, Tang, Shasha, Fang, Yuanyuan, Liu, Yalei, Chen, Yiqi, Zhang, Yun, Yuan, Qian, Shang, Jing, Kan, Quane, Yang, Huihui, Man, Hua, Wang, Danyu, Yuan, Huijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202724/
https://www.ncbi.nlm.nih.gov/pubmed/35397165
http://dx.doi.org/10.1210/clinem/dgac210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202724/
https://www.ncbi.nlm.nih.gov/pubmed/35397165
http://dx.doi.org/10.1210/clinem/dgac210

Ejemplares similares